SciSparc (NASDAQ: SPRC) highlights Clearmind patent move on obesity therapy

Rhea-AI Filing Summary

SciSparc Ltd. furnished a Form 6-K to update investors about a new development in its collaboration with Clearmind. The company reported that on August 7, 2025 it issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” This indicates the partners are pursuing patent protection for a combination therapy aimed at metabolic conditions such as obesity and elevated blood sugar levels.

The Form 6-K also states that this update is incorporated by reference into SciSparc’s existing shelf registration statements on Form F-3 and its equity compensation registration statements on Form S-8, meaning the disclosure becomes part of those securities offering documents.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On August 7, 2025, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-233417, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the SEC to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1 

EXHIBIT INDEX

Exhibit No.
99.1		Press release issued by SciSparc Ltd. titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.”

2 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SciSparc Ltd.
Date: August 8, 2025	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

3 

FAQ

What did SciSparc Ltd. (SPRC) report in this Form 6-K?

SciSparc reported that it issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” The Form 6-K furnishes that press release as an exhibit.

What is the focus of SciSparc’s collaboration with Clearmind mentioned in the filing?

The collaboration led to the publication of an international patent application for a novel combination therapy targeting obesity and high blood sugar, according to the press release title cited in the Form 6-K.

How does this Form 6-K affect SciSparc (SPRC) registration statements?

The Form 6-K is incorporated by reference into SciSparc’s registration statements on Form F-3 and Form S-8, so the information in this report becomes part of those offering documents from the date of submission, unless later superseded.

Does the Form 6-K disclose financial results for SciSparc Ltd.?

No. This Form 6-K describes the furnishing of a press release about an international patent application for a combination therapy and its incorporation into existing registration statements. It does not present financial results.

Who signed the SciSparc Ltd. Form 6-K and in what capacity?

The Form 6-K was signed on behalf of SciSparc Ltd. by Oz Adler, who is identified as the company’s Chief Executive Officer and Chief Financial Officer.

Where can investors find the detailed information about the SciSparc-Clearmind therapy?

The detailed information is in the press release furnished as Exhibit 99.1 to the Form 6-K, titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.”